Bipartisan bill seeks to tighten the domestic pharma supply chain

Drug short­ages have sparked hear­ings, ques­tions over why the US doesn’t do more do­mes­tic man­u­fac­tur­ing, and the var­i­ous caus­es. Now, a new bi­par­ti­san Sen­ate bill is hop­ing to rein in the Amer­i­can’s de­pen­dence on for­eign phar­ma­ceu­ti­cals and APIs.

Sens. Joni Ernst (R-IA) and Gary Pe­ters (D-MI) in­tro­duced the bill last week and it aims to lim­it for­eign man­u­fac­tur­ing for crit­i­cal drugs and re­quires the DOD and the DHS to as­sess the vul­ner­a­bil­i­ties and oth­er na­tion­al se­cu­ri­ty risks to the phar­ma­ceu­ti­cal sup­ply chain.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN